Medik8

About 

Inflexion invested in Medik8, a global, science-led skincare brand, in 2021 before agreeing to sell a majority shareholding in 2025 to L’Oréal Groupe, with Inflexion retaining a minority shareholding in the business.

Founded in 2009 by British scientist Elliot Isaacs, Medik8 is a premium clinical skincare brand offering high-quality active skincare products which deliver clinical results without compromising on experience. Medik8 formulates and manufactures its products in-house at its UK Innovation Centre.

Value acceleration 

During Inflexion’s four-year investment, Medik8 achieved significant global growth, tripling headcount and sales, expanding across Europe and Australia, and strengthening its US presence, with US revenue share increasing sevenfold. Supported by Inflexion, the brand enhanced its digital capabilities, driving a sixfold increase in direct-to-consumer sales, and opened a 100,000 sq. ft. Innovation Centre within the first year, tripling R&D and operational capacity and enabling the launch of several award-winning products. Medik8 today is recognised as a category leader in innovation.

Inflexion also supported the strengthening of the leadership team, with the appointment of a Chair, CEO, US GM and CMO, alongside new roles in digital, data, innovation and sustainability. In 2024, Medik8 achieved B Corp™ certification, underscoring its commitment to sustainability.